Brief: GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster

Geovax Labs

06/02/2024 14:20

Feb 6 (Reuters) - GeoVax Labs Inc  GOVX.O :
    * GEOVAX REPORTS POSITIVE INTERIM DATA FROM PHASE 2 CLINICAL
TRIAL
OF GEO-CM04S1 AS A UNIVERSAL COVID-19 VACCINE BOOSTER
    * GEOVAX LABS INC: RESULTS DEMONSTRATE POTENTIAL PROTECTIVE
IMMUNITY AGAINST MULTIPLE SARS-COV-2 VARIANTS
    * GEOVAX LABS INC: TO DATE, THERE HAVE BEEN NO SERIOUS
ADVERSE
EVENTS, AND ADVERSE EVENTS WERE IN LINE WITH OTHER ROUTINE
VACCINATIONS

Source text for Eikon:  ID:nGNX8mmhbZ 
Further company coverage:  GOVX.O 

 ((Reuters.Briefs@thomsonreuters.com;))